Iphigénie Korakis

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers

Aurélien Voissière, Carlos Gomez‐Roca, Sylvie Chabaud et al. · Science Translational Medicine · 2024 · 54 citations

Medicine, Oncology, Pharmacology +17

Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial

Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan et al. · European Journal of Cancer · 2022 · 50 citations · Full text

Medicine, Oncology, Pharmacology +7

Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.

Stéphane Champiat, Philippe A. Cassier, Nuria Kotecki et al. · Journal of Clinical Oncology · 2021 · 27 citations

Medicine, Oncology, Pharmacotherapy +16

Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.

Elena Garralda, Aung Naing, Vladimir Galvao et al. · Journal of Clinical Oncology · 2022 · 13 citations

Medicine, Oncology, Pharmacology +17

983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor

Nuria Kotecki, Stéphane Champiat, J.P. Delord et al. · Annals of Oncology · 2021 · 12 citations

Medicine, Oncology, Pharmacology +11